Lanreotide acetate salt

Modify Date: 2024-01-04 14:03:43

Lanreotide acetate salt structure	Common Name	Lanreotide acetate salt
	CAS Number	108736-35-2	Molecular Weight	1096.323
	Density	1.4±0.1 g/cm3	Boiling Point	1508.2±65.0 °C at 760 mmHg
	Molecular Formula	C₅₄H₆₉N₁₁O₁₀S₂	Melting Point	N/A
	MSDS	N/A	Flash Point	865.9±34.3 °C

Use of Lanreotide acetate salt

Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].

Name	Lanreotide
Synonym	More Synonyms

Description	Lanreotide (BIM 23014) is a somatostatin analogue with antineoplastic activity. Lanreotide can be used for the research of carcinoid syndrome[1][2].
Related Catalog	Research Areas >> Cancer Research Areas >> Endocrinology Signaling Pathways >> Others >> Others
In Vitro	Lanreotide (BIM 23014) (100 nM; 24-48 h) combines with radiation increasing in apoptotic sub-G1 proportion[1]. Lanreotide results in a dose-dependent decrease in GH3 cell colony forming units. Lanreotide at concentrations of 1, 10, 100, and 1000 nM results in cell survival rates of 75, 56, 39 and 27% respectively. The IC50 is 57 nM[1]. Lanreotide inhibits GH-secreting pituitary adenoma cell proliferation and hormone release in vitro[2].
In Vivo	Lanreotide (2.5-10mg/kg; s.c.; daily for 5 days) results in tumor growth inhibition[1]. Animal Model: Male nude mice, 8 weeks old and 20–25 g in body weight (GH3 tumor-bearing nude mice)[1] Dosage: 2.5, 5, 10 mg/kg Administration: Subcutaneous; daily for 5 days Result: Produced tumor growth inhibition.
References	[1]. Ning S, et al. Lanreotide promotes apoptosis and is not radioprotective in GH3 cells.Endocr Relat Cancer. 2009 Sep;16(3):1045-55. [2]. Florio T, et al. Characterization of the intracellular mechanisms mediating somatostatin and lanreotide inhibition of DNA synthesis and growth hormone release from dispersed human GH-secreting pituitary adenoma cells in vitro.Clin Endocrinol (Oxf). 2003 Jul;59(1):115-28.

Density	1.4±0.1 g/cm3
Boiling Point	1508.2±65.0 °C at 760 mmHg
Molecular Formula	C₅₄H₆₉N₁₁O₁₀S₂
Molecular Weight	1096.323
Flash Point	865.9±34.3 °C
Exact Mass	1095.467041
PSA	405.68000
LogP	2.89
Vapour Pressure	0.0±0.3 mmHg at 25°C
Index of Refraction	1.689

Lanreotide acetate salt MSDS(Chinese)

B-naphthyl-D-ala-cys-tyr-D-trp*lys-val-cys-thr am

1,2-Dithia-5,8,11,14,17-pentaazacycloeicosane-4-carboxamide, 10-(4-aminobutyl)-N-[1-(aminocarbonyl)-2-hydroxypropyl]-19-[[2-amino-3-(2-naphthalenyl)-1-oxopropyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-7-(1-methylethyl)-6,9,12,15,18-pentaoxo-

10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxo-2-butanyl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

Somatuline

AUTOGEL

ANGIOPEPTIN

IPSTYL

DC-13-116

10-(4-Aminobutyl)-N-(1-amino-3-hydroxy-1-oxobutan-2-yl)-16-(4-hydroxybenzyl)-13-(1H-indol-3-ylmethyl)-7-isopropyl-19-{[3-(2-naphthyl)alanyl]amino}-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentaazacycloicosane-4-carboxamide

H-D-2-NAL-CYS-TYR-D-TRP-LYS-VAL-CYS-THR-NH2